brigatinib (Compound)

Synonyms:Brigatinib, 1197953-54-0, ALUNBRIG, AP-26113, UNII-HYW8DB273J, Brigatinib (AP-26113), HYW8DB273J, AP 26113, (2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide, 5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine, 2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)-, 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-, 5-Chloro-N~4~-[2-(Dimethylphosphoryl)phenyl]-N~2~-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl)piperidin-1-Yl]phenyl}pyrimidine-2,4-Diamine, Brigatinib [USAN], Brigatiib, Alunbrig (TN), 5-Chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine, 6GY, Brigatinib (JAN/USAN), Brigatinib [USAN:INN], Brigatinib; AP26113, Brigatinib (AP26113), GTPL7741, CHEMBL3545311, SCHEMBL11916361, EX-A775, AMY10294, BCP17214, BDBM50185140, MFCD29472221, NSC784728, NSC787457, AKOS030257612, ZINC148723177, CS-4278, DB12267, NSC-784728, NSC-787457, SB40412, compound 11q [PMID: 27144831], NCGC00483924-01, (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-,delta5-phosphanone, 5-Chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1- yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-Pyrimidinediamine, AC-29958, AS-75176, HY-12857, DB-118419, FT-0700112, S8229, J3.535.964H, D10866, Q27456393

Pubchem:PUBCHEM:57390074

Id:c707539b-4207-54a4-a8d9-1c70c811cd83

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View brigatinib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for brigatinib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with brigatinib.

Results found

Linked to

	Label	Description
	brigatinib (11ee53b4-63ad-4564-b674-aa61e4cd893e) Collection (Entity type)	Metadatata for brigatinib
	DCSTRUCT ID 05233 Collection (Entity type)	DrugPage Collection: (DrugCentralID:05233; PubChem_CID:68165256, FILE=drugcentral_drug_05233.json)
	brigatinib negatively regulates KRT19 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	brigatinib in similarity relationship with wortmannin Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Brigatinib bioactivity ALK tyrosine kinase receptor Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	brigatinib positively regulates TMPRSS3 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Brigatinib bioactivity Receptor-type tyrosine-protein kinase FLT3 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	brigatinib positively regulates PRUNE2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	brigatinib positively regulates SCGB1D2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	brigatinib negatively regulates PLA2G2A Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS